Shanghai, China, 15 September 2020: LBD Life Sciences is pleased to announce that LBD has been embedded into SPT Life Sciences aggressive growth plans, and became a wholly-owned subsidiary of SPT Life Sciences.

中國，上海，2020年9月15日: LBD Life Sciences Ltd（騰泉生命科技）很高興地宣布：騰泉生命科技已加入英國SPT Life Sciences集團的未來藍圖，成為SPT Life Sciences集團的全資子公司。

For over 10 years, LBD Life Sciences has successfully developed Chinese life science market with its reputation and popularity gradually increased. With close collaboration and continuous support from SPT Labtech, the team has gained customer recognition with dedicated and professional services. We have brought world-leading application knowledge and engineering capabilities to Chinese life science research community to accelerate their researches.

經過十多年的發展，騰泉生命科技成功開拓了中國生命科學市場，在業內有很高知名度。在英國SPT Labtech的緊密合作和持續支持下，我們的團隊以專業的服務贏得了客戶的認可和支持。我們將世界領先的應用科學技術和知識帶到中國的生命科學研究領域，以加速科學家的研究進程。

SPT Labtech, the global leader in liquid handling and sample management, has designed and built a portfolio of high end solutions that help improve efficiency, increase agility, support miniaturization and streamline life science research. The company's products streamline critical workflows and increase agility, efficiency and productivity across drug discovery, structural biology, genomics, Cryo-EM, sample management and biobanking. 

英國SPT Labtech公司作為樣本液體處理和存儲管理的全球領導者，設計并建立了一系列液體處理和樣品管理整體解決方案，幫助提高效率、增加靈活性、支持微縮化、簡化和加速生命科學研究。其產品在藥物發現、結構生物學、基因組學、冷凍電鏡、樣品管理和生物數據庫等領域簡化了關鍵的工作流程，提高了效率、靈活性和創造力。

Patrick Bennett, Group CEO of SPT Life Sciences, said, "We are delighted to complete the deal and we are very excited to bring LBD into the group. This investment highlights SPT Life Sciences commitment to developing a global portfolio of companies with a range of specialties that help life science professionals world-wide to achieve their research goals. For over 10 years, the team at LBD have supported the growing life science research community in China and we believe that this investment will ensure they are able to do so going forward.”

SPT Life Sciences集團首席執行官Patrick Bennett先生表示：“我們很高興完成此次收購，也很高興騰泉生命科技公司加入集團。這項投資彰顯了SPT Life Sciences致力于開發一系列具有生命科學專業知識的全球公司的決心，這些專業知識可以幫助全世界的生命科學專業人士實現其研究目標。十多年來，騰泉生命科技的團隊一直在為不斷壯大的中國生命科學研究領域提供技術支持，我們相信這次收購將確保他們能夠繼續前進。”

Ying Yang, previously chairwoman of LBD Life Science said, “we have witnessed an increasing attention and capital flow into Chinese life science in recent years. With the dramatic increase in needs for improving workflows in drug discovery, structural biology, sample management, biobanking and genomics applications, we believe this integration would further benefit Asia’s research and development community.”

騰泉生命科技前董事長楊穎女士表示:“近年來，隨著藥物發現、結構生物學、樣本管理、生物數據庫和基因組學等對工作流程更加完善化需求的增加，中國生命科學受到了越來越多的關注和資金投入。我們相信，此次收購將進一步惠及亞洲生命科學研發領域。”

Sean Xiao, managing director of LBD Life Science commented “as part of SPT Life Sciences, we will remain deeply committed to solving Asia’s life science customers' toughest research problems by leveraging our global expertise, and enabling access to cutting edge instrumentation. We can see many advantages of being part of the global platform and look forward to our bright future.”

騰泉生命科技總經理肖鋒先生表示:“作為SPT Life Sciences集團的一員，我們將繼續致力于利用我們的專業知識和先進的儀器設備，解決亞洲生命科學客戶最棘手的研究問題。加入SPT Life Sciences集團是我們今后前進道路上的重要源泉和支撐，讓我們一起展望未來，攜手創造亞洲生命科學自動化事業的輝煌！”